Stock Analysis

ImExHS Full Year 2023 Earnings: AU$0.10 loss per share (vs AU$0.085 loss in FY 2022)

Published
ASX:IME

ImExHS (ASX:IME) Full Year 2023 Results

Key Financial Results

  • Revenue: AU$19.9m (up 16% from FY 2022).
  • Net loss: AU$4.19m (loss widened by 38% from FY 2022).
  • AU$0.10 loss per share (further deteriorated from AU$0.085 loss in FY 2022).
ASX:IME Earnings and Revenue History March 1st 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

ImExHS Earnings Insights

Looking ahead, revenue is forecast to grow 20% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Healthcare Services industry in Australia.

Performance of the Australian Healthcare Services industry.

The company's shares are down 4.6% from a week ago.

Risk Analysis

Be aware that ImExHS is showing 2 warning signs in our investment analysis that you should know about...

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.